Disease · MONDO_0018944

gestational trophoblastic neoplasm

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. gestational trophoblastic neoplasm. Diseases, record MONDO_0018944. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0018944

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: gestational trophoblastic neoplasm; Open Targets
Open Targets ID: MONDO_0018944; Open Targets
Other names: GTN, GTT, gestational trophoblastic tumor, gestational trophoblastic tumour; Open Targets
Disease Ontology: DOID:3590; Disease Ontology
NCI Thesaurus: C4699; NCI Thesaurus
Orphanet: ORPHA:59305; Orphanet
Highest stage of its drugs: Phase 3, for 4 of its 17 drugs, from ClinicalTrials.gov; Open Targets

Drugs17

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
METHOTREXATE	CHEMBL34259	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
DACTINOMYCIN	CHEMBL1554	Protein	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
PACLITAXEL	CHEMBL428647	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
CAMRELIZUMAB	CHEMBL4297715	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CAROTUXIMAB	CHEMBL2109321	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DOMVANALIMAB	CHEMBL4650392	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DOSTARLIMAB	CHEMBL4298124	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 17

See all 17 drugs

Targets24

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PDCD1	Programmed cell death protein 1	6	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
DHFR	Dihydrofolate reductase	3	Dihydrofolate reductase inhibitor	Phase 3	https://conductscience.org/library/genes/1719	Drugs and targets
GART	Trifunctional purine biosynthetic protein adenosine-3	2	GAR transformylase inhibitor	Phase 2	https://conductscience.org/library/genes/2618	Drugs and targets
TYMS	Thymidylate synthase	2	Thymidylate synthase inhibitor	Phase 2	https://conductscience.org/library/genes/7298	Drugs and targets
CTLA4	Cytotoxic T-lymphocyte protein 4	1	Cytotoxic T-lymphocyte protein 4 inhibitor	Phase 2	https://conductscience.org/library/genes/1493	Drugs and targets
ENG	Endoglin	1	Endoglin inhibitor	Phase 2	https://conductscience.org/library/genes/2022	Drugs and targets
KDR	Vascular endothelial growth factor receptor 2	1	Vascular endothelial growth factor receptor 2 inhibitor	Phase 2	https://conductscience.org/library/genes/3791	Drugs and targets
TIGIT	T-cell immunoreceptor with Ig and ITIM domains	1	T-cell immunoreceptor with Ig and ITIM domains inhibitor	Phase 2	https://conductscience.org/library/genes/201633	Drugs and targets
TUBA1A	Tubulin	1	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	1	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/10376	Drugs and targets

1 to 10 of 24

See all 24 targets

Trials15

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01535053	Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia	Phase 3	57	2019-08-13	Choriocarcinoma, FIGO Stage I Gestational Trophoblastic Tumor, FIGO Stage II Gestational Trophoblastic Tumor, FIGO Stage III Gestational Trophoblastic Tumor, Hydatidiform Mole	DACTINOMYCIN, METHOTREXATE	Open Targets' reading of its record	ClinicalTrials.gov
NCT02664961	Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)	Phase 2	3	2019-06-04	Gestational Trophoblastic Neoplasia, Choriocarcinoma, Placental Site Trophoblastic Tumor, Epithelioid Trophoblastic Tumor	BEVACIZUMAB, CAROTUXIMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT02834013	Nivolumab and Ipilimumab in Treating Patients With Rare Tumors	Phase 2	798		Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma, Adrenal Gland Pheochromocytoma, Anal Canal Neuroendocrine Carcinoma, Anal Canal Undifferentiated Carcinoma, Angiosarcoma, Apocrine Neoplasm, Appendix Mucinous Adenocarcinoma, Bartholin Gland Transitional Cell Carcinoma, Basal Cell Carcinoma, Bladder Adenocarcinoma, Breast Metaplastic Carcinoma, Cervical Adenocarcinoma, Cholangiocarcinoma, Chordoma, Colorectal Squamous Cell Carcinoma, Desmoid Fibromatosis, Endometrial Transitional Cell Carcinoma, Endometrioid Adenocarcinoma, Esophageal Neuroendocrine Carcinoma, Esophageal Undifferentiated Carcinoma, Extrahepatic Bile Duct Carcinoma, Extramammary Paget Disease, Fallopian Tube Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fibromyxoid Tumor, Gallbladder Carcinoma, Gastric Neuroendocrine Carcinoma, Gastric Squamous Cell Carcinoma, Gastric Undifferentiated Carcinoma, Gastrointestinal Stromal Tumor, Gestational Trophoblastic Tumor, Giant Cell Carcinoma, Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type, Intestinal Neuroendocrine Carcinoma, Intrahepatic Cholangiocarcinoma, Lung Neuroendocrine Tumor, Lung Sarcomatoid Carcinoma, Major Salivary Gland Carcinoma, Malignant Neoplasm of Unknown Primary, Malignant Odontogenic Neoplasm, Malignant Peripheral Nerve Sheath Tumor, Malignant Solid Neoplasm, Malignant Testicular Sex Cord-Stromal Tumor, Metastatic Pituitary Neuroendocrine Tumor, Minimally Invasive Lung Adenocarcinoma, Mixed Mesodermal (Mullerian) Tumor, Mucinous Adenocarcinoma, Mucinous Cystadenocarcinoma, Nasal Cavity Adenocarcinoma, Nasal Cavity Carcinoma, Nasopharyngeal Carcinoma, Nasopharyngeal Low Grade Papillary Adenocarcinoma, Nasopharyngeal Undifferentiated Carcinoma, Oral Cavity Carcinoma, Oropharyngeal Undifferentiated Carcinoma, Ovarian Adenocarcinoma, Ovarian Germ Cell Tumor, Ovarian Mucinous Adenocarcinoma, Ovarian Squamous Cell Carcinoma, Ovarian Transitional Cell Carcinoma, Pancreatic Acinar Cell Carcinoma, Pancreatic Neuroendocrine Carcinoma, Paraganglioma, Paranasal Sinus Adenocarcinoma, Paranasal Sinus Carcinoma, Parathyroid Gland Carcinoma, PEComa, Penile Squamous Cell Carcinoma, Peritoneal Mesothelial Neoplasm, Placental Choriocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Pseudomyxoma Peritonei, Rare Disorder, Scrotal Squamous Cell Carcinoma, Seminal Vesicle Adenocarcinoma, Seminoma, Serous Cystadenocarcinoma, Small Intestinal Adenocarcinoma, Small Intestinal Squamous Cell Carcinoma, Spindle Cell Neoplasm, Teratoma With Somatic-Type Malignancy, Testicular Non-Seminomatous Germ Cell Tumor, Thyroid Gland Carcinoma, Tracheal Carcinoma, Transitional Cell Carcinoma, Ureter Adenocarcinoma, Ureter Squamous Cell Carcinoma, Urethral Adenocarcinoma, Urethral Squamous Cell Carcinoma, Vaginal Adenocarcinoma, Vaginal Squamous Cell Carcinoma, Not Otherwise Specified, Vulvar Carcinoma	IPILIMUMAB, NIVOLUMAB	Its record names the disease	ClinicalTrials.gov
NCT02639650	Study of Paclitaxel Plus Cisplatin as the First-line Chemotherapy in High Risk Gestational Trophoblastic Tumor	Phase 3	214		Gestational Trophoblastic Neoplasms	CISPLATIN, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT03703271	Study of Hysteroscopic Repeat Curettage as the First-line Treatment in Low-risk Postmolar Gestational Trophoblastic Neoplasia	Phase 2	70		Gestational Trophoblastic Neoplasia	METHOTREXATE	Open Targets' reading of its record	ClinicalTrials.gov
NCT05139095	Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia	Phase 2	70		Gestational Trophoblastic Neoplasia	CAMRELIZUMAB, RIVOCERANIB	Open Targets' reading of its record	ClinicalTrials.gov
NCT00096187	Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Low-Risk Gestational Trophoblastic Tumor After a Molar Pregnancy	Phase 2	55		Gestational Trophoblastic Tumor	PEMETREXED DISODIUM	Its record names the disease	ClinicalTrials.gov
NCT00190918	A Trial for Patients With Gestational Trophoblastic Disease	Phase 2	50		Trophoblastic Neoplasms, Uterine Neoplasms, Hydatidiform Mole, Choriocarcinoma	PEMETREXED	Its record names the disease	ClinicalTrials.gov
NCT06790706	IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers	Phase 2	27		Peritoneal Mesothelioma, Gestational Trophoblastic Tumor, Anaplastic Thyroid Carcinomas, Gastroenteropancreatic Neuroendocrine Tumor, Carcinoid Tumor, Thymic Carcinoma	DOMVANALIMAB, ZIMBERELIMAB	Its record names the disease	ClinicalTrials.gov
NCT02606539	Surgery Plus Single Agent Chemotherapy Versus Primary Chemotherapy for Gestational Trophoblastic Neoplasms	Phase 2/3	20		Gestational Trophoblastic Neoplasms	METHOTREXATE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 15

See all 15 trials

Comparisons in its trials4

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Regimen I (Dactinomycin) vs Regimen II (Methotrexate): deaths from any cause	0 of 29	0 of 28	57	NCT01535053	Trial comparisons
Regimen I (Dactinomycin) vs Regimen II (Methotrexate): serious adverse events	1 of 28	1 of 26	54	NCT01535053	Trial comparisons
Regimen I (Dactinomycin) vs Regimen II (Methotrexate): The Number of Participants With Post Protocol Multi-agent Chemotherapy Treatment for Each Arm.	0 of 7	0 of 5	12	NCT01535053	Trial comparisons
Regimen I (Dactinomycin) vs Regimen II (Methotrexate): The Number of Participants With Post Protocol Surgical Treatment for Each Arm.	0 of 7	0 of 5	12	NCT01535053	Trial comparisons

Papers from its trials19

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
42499790	DERIVED	1	PubMed
41995270	DERIVED	1	PubMed
41892875	DERIVED	1	PubMed
41672597	DERIVED	1	PubMed
40588371	DERIVED	1	PubMed
40402690	DERIVED	1	PubMed
39856213	DERIVED	1	PubMed
39583952	DERIVED	1	PubMed
39417692	DERIVED	1	PubMed
39343510	DERIVED	1	PubMed

1 to 10 of 19

See all 19 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0018944

GET https://conductscience.org/api/diseases/v1/MONDO_0018944/targets?page=2

API reference For AI assistants